Human Platelet Lysate (hPL) is a human-derived, xeno-free alternative to fetal bovine serum (FBS), developed to address the scientific, ethical, and translational limitations of animal-derived supplem...
Read moreOn Tuesday, November 18, the consortium of the European project MILenARI (Mediterranean International Lentivirus ARI) held its inaugural meeting online, with the participation of all partners and repr...
Read moreThe CNIO, Spain's leading cancer research center, focuses its scientific, technological, and human resources on the major challenges currently faced by cancer research.
Read moreThese projects aim to validate hyperspectral technology for improving assisted reproduction, using bioprinted cell spheroids to combat type 1 diabetes and developing light-activated drugs to restore v...
Read moreHan demostrado que la interleuquina 33 (IL-33), una proteína implicada en la regulación de las células inmunes, aplicada en el contexto de la terapia celular adoptiva, es capaz de modular la respue...
Read moreLas células utilizadas en la terapia corresponden a una subpoblación CD133+ derivada de médula ósea, previamente caracterizada por su capacidad regenerativa en el tejido endometrial, lo que refuer...
Read moreEn el Día Mundial del Cáncer, especialistas del Cancer Center Clínica Universidad de Navarra destacan los grandes avances en el diagnóstico, tratamiento y seguimiento integral de los pacientes onc...
Read moreCancer remains a leading cause of death worldwide. Sartorius helps to simplify the development and manufacturing of personalized cancer therapies.
Read moreThe importance of supply chain management in pharma extends far beyond operational efficiency. It directly determines whether a child in rural Kenya receives the same quality of vaccine as one in Bost...
Read moreA multidisciplinary Clínic-IDIBAPS team, part of the Clínic Barcelona Comprehensive Cancer Centre (4CB), has published phase 2 results of the CAR-T ARI-0001 (varnimcabtagene autoleucel) for treating...
Read moreA CAR-T therapy targeting the CD84 protein—an emerging therapeutic target in hematologic malignancies characterized by its high expression in leukemic cells— will be evaluated for the first time
Read moreDentro del total de la financiación anunciada, la Ayuda Estudios Clínicos AECC, dotada de un millón de euros, apoya un pionero ensayo clínico con virus modificados para el tratamiento de tumores c...
Read more